Research on the effectiveness of beauticians' measures of hand skin protection

Badania prowadzone w środowisku kosmetyczek wykazały, że zmiany chorobowe występujące na skórze rąk są zjawiskiem częstym. Prawie połowa, bo aż 46% badanych stwierdza, że ich dłonie są przesuszone, 32% uważa, że szorstkie, 12% ankietowanych zaobserwowało łuszczenie, 8% zaczerwienienie, a 2% inne objawy. Po 30 dniach stosowania kremu ochronnego 90% badanych zauważyło znaczną poprawę stanu skóry rąk, 8% uważa, ze nastąpiła lekka poprawa. Zastosowanie przez kosmetyczki opracowanych w CIOP-PIB środków ochrony skóry pozwoliło na znaczne zmniejszenie dolegliwości skóry rąk.Hand contact dermatitis often affects health care workers, food industry workers, hairdressers, cleaners, rubber industry workers, printers, metal plant workers and beauticians. Implementation of skin protection measures developed in CIOP-PIB by beauticians minimalized their hand skin disorders

The composition of waterproof barrier creams' ingredients and their barrier properties

Ochrona skóry rąk jest ważna z uwagi na rosnącą ilość zachorowań na kontaktowe zapalenie skóry spowodowane przez substancje szkodliwe lub drażniące. Najlepszą ochronę stanowią rękawiczki, lecz gdy ich stosowanie jest niewskazane można używać środki ochrony skóry, które są skuteczne o ile są prawidłowo dobrane. Wyniki badań laboratoryjnych potwierdziły wnioski wynikające z analizy substratów, użytych do produkcji wodoodpornych kremów ochronnych. Najlepsze właściwości ochronne, zgodne z deklaracją producenta, miał preparat zawierający głównie substancje barierowe, bez dodatków kosmetycznych.Hands' skin protection is important due to growing number of cases of contact dermatitis, caused by contact with harmful or irritating substances. The best protection provide gloves, but when the use of them is not recommended skin protection measure can be applied, on condition that it has apropriate barrier properties. Laboratory tests for assessing effectiveness of barrier hydrophobic preparations confirmed the conclusions from the analysis of substrates used in their production. The best hydrophobic properties had a preparation which contain only barrier substances, without cosmetic additives

A Survey of Work-Related Skin Diseases in Different Occupations in Poland

Occupational skin disorders, in particular inflammations, dryness and erythema, in 80% of cases affect the skin of hands. The most frequent diagnosis, in over 90% of cases of occupational skin diseases, points to an irritant or allergic contact dermatitis. Our aim was to study the prevalence of self-reported skin symptoms on hands and forearms in different populations. The study was conducted on 581 healthcare workers, 61 hair stylists, 149 beauticians, 90 food services workers, 90 cleaners, 181 metal factory workers and 69 textile workers. Healthcare workers had greatest exposure. Eighty-six percent of dentists, 67% of midwives, 51% of nurses and 41% of physicians reported skin disorders. Problems with latex gloves were declared by 30% of healthcare workers. Thirty-four percent of food services workers, 24% of textile workers, 30% of metal factory workers, 21% of hair stylists and beauticians, and 64% of cleaners reported skin manifestations during the time of employment, which they thought could be work-related

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

Background Current systemic treatments for children younger than 6 years with moderate-to-severe atopic dermatitis that is uncontrolled with topical therapies might have suboptimal efficacy and safety. Dupilumab is approved for older children and adults with atopic dermatitis and for other type 2 inflammatory conditions. We aimed to evaluate efficacy and safety of dupilumab with concomitant low-potency topical corticosteroids in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis. Methods This randomised, double-blind, placebo-controlled, parallel-group, phase 3 trial was conducted in 31 hospitals, clinics, and academic institutions in Europe and North America. Eligible patients were aged 6 months to younger than 6 years, with moderate-to-severe atopic dermatitis (Investigator's Global Assessment [IGA] score 3–4) diagnosed according to consensus criteria of the American Academy of Dermatology, and an inadequate response to topical corticosteroids. Patients were randomly assigned (1:1) to subcutaneous placebo or dupilumab (bodyweight ≥5 kg to <15 kg: 200 mg; bodyweight ≥15 kg to <30 kg: 300 mg) every 4 weeks plus low-potency topical corticosteroids (hydrocortisone acetate 1% cream) for 16 weeks. Randomisation was stratified by age, baseline bodyweight, and region. Patient allocation was done via a central interactive web response system, and treatment allocation was masked. The primary endpoint at week 16 was the proportion of patients with IGA score 0–1 (clear or almost clear skin). The key secondary endpoint (coprimary endpoint for the EU and EU reference market) at week 16 was the proportion of patients with at least a 75% improvement from baseline in Eczema Area and Severity Index (EASI-75). Primary analyses were done in the full analysis set (ie, all randomly assigned patients, as randomly assigned) and safety analyses were done in all patients who received any study drug. This study was registered with ClinicalTrials.gov, NCT03346434. Findings Between June 30, 2020, and Feb 12, 2021, 197 patients were screened for eligibility, 162 of whom were randomly assigned to receive dupilumab (n=83) or placebo (n=79) plus topical corticosteroids. At week 16, significantly more patients in the dupilumab group than in the placebo group had IGA 0–1 (23 [28%] vs three [4%], difference 24% [95% CI 13–34]; p<0·0001) and EASI-75 (44 [53%] vs eight [11%], difference 42% [95% CI 29–55]; p<0·0001). Overall prevalence of adverse events was similar in the dupilumab group (53 [64%] of 83 patients) and placebo group (58 [74%] of 78 patients). Conjunctivitis incidence was higher in the dupilumab group (four [5%]) than the placebo group (none). No dupilumab-related adverse events were serious or led to treatment discontinuation. Interpretation Dupilumab significantly improved atopic dermatitis signs and symptoms versus placebo in children younger than 6 years. Dupilumab was well tolerated and showed an acceptable safety profile, similar to results in older children and adults. Funding Sanofi and Regeneron Pharmaceutical